@article{2f8f5382f57643d991125b013f35911e,
title = "Modeling autosomal dominant Alzheimer's disease with machine learning",
abstract = "Introduction: Machine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer's disease. Methods: Longitudinal structural magnetic resonance imaging, amyloid positron emission tomography (PET), and fluorodeoxyglucose PET were acquired in 131 mutation carriers and 74 non-carriers from the Dominantly Inherited Alzheimer Network; the groups were matched for age, education, sex, and apolipoprotein ε4 (APOE ε4). A deep neural network was trained to predict disease progression for each modality. Relief algorithms identified the strongest predictors of mutation status. Results: The Relief algorithm identified the caudate, cingulate, and precuneus as the strongest predictors among all modalities. The model yielded accurate results for predicting future Pittsburgh compound B (R2 = 0.95), fluorodeoxyglucose (R2 = 0.93), and atrophy (R2 = 0.95) in mutation carriers compared to non-carriers. Discussion: Results suggest a sigmoidal trajectory for amyloid, a biphasic response for metabolism, and a gradual decrease in volume, with disease progression primarily in subcortical, middle frontal, and posterior parietal regions.",
keywords = "Pittsburgh compound B (PiB), autosomal dominant Alzheimer's disease (ADAD), fluorodeoxyglucose (FDG), machine learning, magnetic resonance imaging (MRI)",
author = "{for the Dominantly Inherited Alzheimer Network (DIAN)} and Luckett, {Patrick H.} and Austin McCullough and Gordon, {Brian A.} and Jeremy Strain and Shaney Flores and Aylin Dincer and John McCarthy and Todd Kuffner and Ari Stern and Meeker, {Karin L.} and Berman, {Sarah B.} and Chhatwal, {Jasmeer P.} and Carlos Cruchaga and Fagan, {Anne M.} and Farlow, {Martin R.} and Fox, {Nick C.} and Mathias Jucker and Johannes Levin and Masters, {Colin L.} and Hiroshi Mori and Noble, {James M.} and Stephen Salloway and Schofield, {Peter R.} and Brickman, {Adam M.} and Brooks, {William S.} and Cash, {David M.} and Fulham, {Michael J.} and Bernardino Ghetti and Jack, {Clifford R.} and Jonathan V{\"o}glein and William Klunk and Robert Koeppe and Hwamee Oh and Yi Su and Michael Weiner and Qing Wang and Laura Swisher and Dan Marcus and Deborah Koudelis and Nelly Joseph-Mathurin and Lisa Cash and Chengjie Xiong and Perrin, {Richard J.} and Karch, {Celeste M.} and Jason Hassenstab and Eric McDade and Morris, {John C.} and Benzinger, {Tammie L.S.} and Bateman, {Randall J.} and Ances, {Beau M.}",
note = "Funding Information: informationThis research was funded by the National Institutes of Health (NIH; grant numbers K01AG053474, R01AG052550, UFAG 032438, UL1TR000448, P30NS098577, R01EB009352, P50AG05131, U01AG042791, U01AG042791-S1 [FNIH and Accelerating Medicines Partnership], R1AG046179); the German Center for Neurodegenerative Diseases (DZNE); the National Institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Centre; and the Medical Research Council Dementias Platform UK (grant numbers MR/L023784/1, MR/009076/1), BrightFocus Foundation A2018817F, Alzheimer Association International Research Grant Program #AARFD-20-681815, NSF DMS 156243, and an anonymous organization.We would like to acknowledge the participants and their families, without whom these studies would not be possible. We additionally thank all of the participating researchers and coordinators in the DIAN (https://dian.wustl.edu/our-research/observational-study/dian-observational-study-sites/) who support the studies. DIAN ClinicalTrials.gov identifier: NCT00869817. Funding Information: The authors declare no conflicts of interest. Anne Fagan received research funding from the National Institute on Aging of the National Institutes of Health, Biogen, Centene, Fujirebio, and Roche Diagnostics. She is a member of the scientific advisory boards for Roche Diagnostics, Genentech, and AbbVie and also consults for Araclon/Grifols, DiademRes, DiamiR, and Otsuka. Carlos Cruchaga receives research support from Biogen, EISAI, Alector, and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Dr. Cruchaga is also a member of the advisory board of ADx Healthcare, Halia Therapeutics, and Vivid Genomics. Jasmeer P. Chhatwal served on the medical advisory board for Otsuka Pharmaceuticals. Johannes Levin reports speaker's fees from Bayer Vital, speaker's fees from Willi Gross Foundation, consulting fees from Axon Neuroscience, consulting fees from Ionis Pharmaceuticals, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers, compensation for work as part‐time CMO from MODAG GmbH, and non‐financial support from AbbVie outside the submitted work. John Morris is funded by NIH grants (numbers P50AG005681, P01AG003991, P01AG026276, UF1AG032438). Dr. Jack serves on an independent data monitoring board for Roche and has served as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer Disease Research Professorship of the Mayo Clinic. Eric McDade is involved in a clinical trial on AV‐1451 sponsored by Avid and serves on a data safety monitoring committee for Eli‐Lilly. Randall Bateman is on the scientific advisory board of C2N Diagnostics and reports research support from AbbVie, Biogen, Eisai, Eli Lilly, Co/Avid Radiopharmaceuticals, Roche, Janssen, and United Neuroscience. Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",
year = "2021",
month = jun,
doi = "10.1002/alz.12259",
language = "English",
volume = "17",
pages = "1005--1016",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
number = "6",
}